Hospital
Dekalb Memorial Hospital, INC
Dekalb Memorial Hospital, INC was paid $9.08M by Medicaid between Jan 2018 and Nov 2024, across 100 billing codes. Its largest line is 99283, emergency room visit (moderate) — 38% of everything it billed.
33Billing provider infoDEKALB MEMORIAL HOSPITAL, INC
AUBURN, IN 46706
AUBURN, IN 46706
33aNPI1902897937assigned 10/31/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$9.08M
24GClaims176,912
24DCodes billed100
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,920 | $493K | |
| 2019 | 22,675 | $725K | |
| 2020 | 15,616 | $757K | |
| 2021 | 28,937 | $1.59M | |
| 2022 | 33,482 | $2.05M | |
| 2023 | 30,539 | $2.18M | |
| 2024incomplete | 17,743 | $1.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 38% | 20,109 | 17,348 | $3.44M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 10,110 | 8,143 | $1.50M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 5.6% | 4,508 | 3,305 | $511K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.5% | 8,273 | 6,480 | $497K |
| 71045 | Radiologic examination, chest; single view | 5.4% | 4,347 | 3,386 | $489K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.8% | 3,593 | 2,657 | $341K |
| A0425 | Ground mileage, per statute mile | 3.3% | 12,863 | 8,115 | $303K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.9% | 1,376 | 1,058 | $260K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 2,303 | 2,012 | $253K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 2,516 | 2,153 | $149K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 813 | 249 | $112K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 272 | 210 | $98K |
88 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,375 | $90K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 789 | $90K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 761 | $82K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,208 | $81K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,043 | $77K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,261 | $76K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,497 | $71K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,069 | $41K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 455 | $40K |
| 80076 | <1% | 8,288 | $37K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,587 | $33K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,289 | $32K |
| 99221 | <1% | 56 | $27K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 69 | $25K |
| 84484 | <1% | 3,250 | $24K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,901 | $24K |
| 99285 | Emergency room visit (most serious) | <1% | 297 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 211 | $21K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 518 | $21K |
| 83690 | <1% | 7,067 | $20K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 612 | $16K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 145 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 537 | $13K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 116 | $13K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,279 | $12K |
| 99219 | <1% | 35 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 259 | $11K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 30 | $10K |
| 81001 | <1% | 5,611 | $9K | |
| 83880 | <1% | 493 | $9K | |
| 83735 | <1% | 2,427 | $8K | |
| 99217 | <1% | 36 | $8K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 83 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 118 | $5K |
| 80061 | Lipid panel | <1% | 669 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,160 | $5K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 30 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 771 | $3K |
| 84703 | <1% | 752 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,710 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 50 | $2K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 48 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 149 | $2K |
| 81003 | <1% | 1,287 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 274 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 131 | $2K |
| 87660 | <1% | 66 | $1K | |
| 87510 | <1% | 66 | $1K | |
| 87480 | <1% | 66 | $1K | |
| 85027 | <1% | 321 | $848.75 | |
| 84439 | <1% | 113 | $837.89 | |
| 87081 | <1% | 135 | $792.41 | |
| 87634 | <1% | 18 | $772.20 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 32 | $602.91 |
| 81025 | <1% | 79 | $587.77 | |
| 87070 | <1% | 64 | $433.44 | |
| 82962 | <1% | 158 | $407.44 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $382.49 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $382.49 |
| 82607 | <1% | 28 | $351.76 | |
| 85379 | <1% | 52 | $342.02 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $337.61 |
| 84460 | <1% | 93 | $336.52 | |
| 87077 | <1% | 47 | $331.83 | |
| 83605 | <1% | 62 | $298.20 | |
| 82533 | <1% | 21 | $286.36 | |
| 89220 | <1% | 15 | $216.23 | |
| 82077 | <1% | 23 | $195.15 | |
| 84481 | <1% | 14 | $192.32 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 15 | $166.32 |
| 80306 | <1% | 14 | $134.06 | |
| 87807 | <1% | 15 | $120.04 | |
| 87186 | <1% | 19 | $103.68 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 38 | $79.15 |
| 85610 | <1% | 48 | $63.22 | |
| 86850 | <1% | 15 | $55.55 | |
| 86592 | <1% | 13 | $33.12 | |
| 93041 | <1% | 32 | $8.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,042 | $3.02 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 52 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 46 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 15 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 39 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 670 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 192 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 132 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 73 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLAGHORN, BRET (VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Dekalb Memorial Hospital, INC | Auburn, IN | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.